Arcadia has built a portfolio of over-the-counter medicines and wellness brands, including Nizoral, Colace, Senokot, CloSYS, Betadine, and Kaopectate. During Mubadala's investment period, the company's revenue tripled and profitability improved materially. 'It has been a privilege to partner with Bansk, Mike DeBiasi and the Arcadia team over the past four years,' Philip Yifei Bao, director of private equity at Mubadala, said in a statement. 'We are incredibly proud to have supported the transformation of Arcadia into the leading North American consumer health and wellness platform.' Subscribe to our Newsletter to increase your edge. Don't worry about the news anymore, through our newsletter you'll receive weekly access to what is happening. Join 120,000 other PE professionals today....
In just the past week, OpenAI bought health startup Torch, Anthropic launched Claude for Health, and Sam Altman-backed Merge Labs closed a $250 million seed round at an $850 million valuation. The money and products are pouring into health and voice AI, but so are concerns about hallucination risks, inaccurate medical information, and massive security vulnerabilities in systems handling sensitive patient data. Today on TechCrunch's Equity podcast, Kirsten Korosec, Anthony Ha, and Sean O'Kane dig into why the AI world is suddenly obsessed with healthcare, what other products can expect an AI-makeover, and more. Theresa Loconsolo is an audio producer at TechCrunch focusing on Equity, the network's flagship podcast. Before joining TechCrunch in 2022, she was one of 2 producers at a four-station conglomerate where she wrote, recorded, voiced and edited content, and engineered live performances and interviews from guests like lovelytheband. Theresa is based in New Jersey and holds a bachelors degree in Communication from Monmouth University....
'I recently had a patient come in, and when I recommended a medication, they had a dialogue printed out from ChatGPT that said this medication has a 45% chance of pulmonary embolism,' Dr. Bari told TechCrunch. When Dr. Bari investigated further, he found that the statistic was from a paper about the impact of that medication in a niche subgroup of people with tuberculosis, which didn't apply to his patient. ChatGPT Health, which will roll out in the coming weeks, allows users to talk to the chatbot about their health in a more private setting, where their messages won't be used as training data for the underlying AI model. 'I think it's great,' Dr. Bari said. 'It is something that's already happening, so formalizing it so as to protect patient information and put some safeguards around it ['] is going to make it all the more powerful for patients to use.' Users can get more personalized guidance from ChatGPT Health by uploading their medical records and syncing with apps like Apple Health and MyFitnessPal. For the security-minded, this raises immediate red flags....
Dealmaking was powered by a sharp rise in transactions exceeding $1bn, offsetting a tariff-related slowdown in the second quarter. Investors announced 445 buyouts during the year, the second-highest total on record, while exit value surged to an estimated $156bn, up from $54bn in 2024. Sponsor-to-sponsor activity played a central role in the rebound. Bain estimates more than 150 such deals in 2025, with aggregate value exceeding $120bn. More than 30 sponsor-to-sponsor transactions were valued above $1bn, compared with just eight the previous year. Biopharma accounted for the largest share of deal value, rising to about $80bn, while provider services reached roughly $62bn, driven by healthcare IT and technology-enabled assets. Medtech also gained momentum, with deal value nearly doubling to around $33bn. Regionally, Europe saw deal value double year-on-year to about $59bn, while North America recorded $90bn of exits. Asia-Pacific also posted record deal value, exceeding its previous peak despite continued volatility....
